Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

219.16 +0.12 (+0.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,680,751
Open 219.31
Bid (Size) 217.00 (100)
Ask (Size) 219.50 (100)
Prev. Close 219.04
Today's Range 217.09 - 220.99
52wk Range 163.81 - 244.81
Shares Outstanding N/A
Dividend Yield 2.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call
AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales... 
Via StockStory
Topics Earnings
3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November
These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+22.1%
+22.1%
1 Month
-5.2%
-5.2%
3 Month
+10.7%
+10.7%
6 Month
+18.7%
+18.7%
1 Year
+9.3%
+9.3%

More News

Read More
US Economic Resilience Fuels Dollar's Ascent Amidst Global Shifts
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
What the Options Market Tells Us About AbbVie
Via Benzinga
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients
Via Stocktwits
2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon
Via The Motley Fool
Topics Intellectual Property
ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure
Via StockStory
Looking Into AbbVie Inc's Recent Short Interest
Via Benzinga
My Favorite Dividend King to Buy in November
Via The Motley Fool
Topics Intellectual Property
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Economy Intellectual Property
2 Top ETFs I Can't Wait to Buy More of in My Retirement Account This November
Via The Motley Fool
Topics ETFs Retirement Stocks
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
Via MarketBeat
Why AbbVie Stock Flopped on Friday
Via The Motley Fool
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Via MarketMinute
Topics Intellectual Property
Exploring the top movers within the S&P500 index during today's session.
Via Chartmill
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
Discover which S&P500 stocks are making waves on Friday.
Via Chartmill
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Why AbbVie (ABBV) Shares Are Falling Today
Via StockStory
Topics World Trade
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Via Benzinga
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
Via Benzinga
Gapping S&P500 stocks in Friday's session
Via Chartmill
AbbVie Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Economy
ABBVIE INC (NYSE:ABBV) Reports Mixed Q3 2025 Results with EPS Beat and Revenue Miss
Via Chartmill

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 219.16
When was AbbVie last traded?
The last trade of AbbVie was at 11/07/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.